Company News

Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US…

Orthocell has today announced that it has received firm commitments for a $17 million capital raising via an institutional placement.

Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of…

Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+™ and Remplir™.

Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+™ in the…

Petra Capital has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share. The report summarises Orthocell’s revenue growth, and…

Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+™ in Singapore,…

Orthocell has announced the accelerated market expansion of Striate+™ and Remplir™, with seven regulatory applications either in progress or planned…

Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental…

Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million…